Morepen Laboratories Ltd launches its first U.S. prescription generic, Desloratadine Tablets USP 5 mg
- Morepen Bio Inc., its wholly owned U.S. subsidiary, is marketing the tablets in 100-count and 500-count packs.
- The launch extends the company’s U.S. business from APIs into finished-dose medicines and distribution.
- Its first U.S. FDA ANDA, for Sitagliptin tablets in three strengths, remains under regulatory review.
